Featured Research

from universities, journals, and other organizations

Two-drug combination improves survival in pancreatic cancer

Date:
October 17, 2013
Source:
Vall d´Hebron Institute of Oncology (VHIO)
Summary:
Investigators have published results of a study showing that administering paclitaxel and gemcitabine in combination significantly improves one- and two-year survival in patients with advanced pancreatic cancer versus gemcitabine alone, the first-line treatment or most standard approach for this type of cancer to date.

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine. Results show that administering these two drugs in combination significantly improves one- and two-year survival in patients with advanced pancreatic cancer versus gemcitabine alone, the first-line treatment or most standard approach for this type of cancer to date.

The new drug is set to become a reference in advanced pancreatic cancer treatment

A multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia, shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now.

The clinical trial, sponsored by Celgene Corporation, involved 861 patients, half of whom were administered the nab-paclitaxel/gemcitabine combination, while the other half received gemcitabine alone. Median overall survival was 8.5 months for nab-paclitaxel/gemcitabine versus 6.7 months for gemcitabine alone. One-year survival rates were 35% and 22%, respectively, and two-year survival rates were 9% and 4%, respectively. Similar side effects were found in the new drug and gemcitabine alike. The trial report therefore concluded that the nab-paclitaxel/gemcitabine combination significantly improves overall survival and response rate in patients with advanced pancreatic cancer.

Dr Josep Tabernero, Head of the Medical Oncology Department at the Vall d´Hebron University Hospital, Director of the Vall d´Hebron Institute of Oncology (VHIO), and one of the co-authors of the study, confirmed that "the results of this study take a step in the right direction towards controlling advanced pancreatic cancer, a disease with a very poor prognosis. We are confident that the gemcitabine/nab-paclitaxel combination will become one of the reference treatments for this disease. New drugs in the pipeline in this field are already being gauged against this combination as the benchmark to beat. Along these lines, investigators at VHIO are developing promising laboratory model combinations for pancreatic cancer treatment."

New first-line treatment for pancreatic cancer

Pancreatic cancer is the fourth leading cause of cancer-related death in Europe and the United States. Gemcitabine therapy has been the standard first-line treatment in patients with unresectable, locally advanced or metastatic pancreatic cancer since 1997. In metastatic disease, one-year survival ranges from about 17 to 23%, while five-year survival is only 2%.

Although numerous phase II and III studies have been conducted on new drugs combined with gemcitabine, most have not shown significant improvement in survival among these patients. The nab-paclitaxel/gemcitabine combination opens a new treatment avenue in this patient population.


Story Source:

The above story is based on materials provided by Vall d´Hebron Institute of Oncology (VHIO). Note: Materials may be edited for content and length.


Journal Reference:

  1. Daniel D. Von Hoff, Thomas Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A. Tjulandin, Wen Wee Ma, Mansoor N. Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel Laheru, Nathan Bahary, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, Jose Iglesias, Markus F. Renschler. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine, 2013; 131016140055001 DOI: 10.1056/NEJMoa1304369

Cite This Page:

Vall d´Hebron Institute of Oncology (VHIO). "Two-drug combination improves survival in pancreatic cancer." ScienceDaily. ScienceDaily, 17 October 2013. <www.sciencedaily.com/releases/2013/10/131017080256.htm>.
Vall d´Hebron Institute of Oncology (VHIO). (2013, October 17). Two-drug combination improves survival in pancreatic cancer. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2013/10/131017080256.htm
Vall d´Hebron Institute of Oncology (VHIO). "Two-drug combination improves survival in pancreatic cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131017080256.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) — The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) — An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) — Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) — Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins